Datroway qhov kev pom zoo yog nyob ntawm cov txiaj ntsig ntawm Theem 3 kev sim tshuaj TROPION-Lub mis01. Cov ntaub ntawv sim tau pom tias Datroway txo qhov kev pheej hmoo ntawm kev kis kab mob lossis tuag hauv cov neeg mob los ntawm 37% piv rau cov kws kho mob xaiv los ntawm cov kws tshawb fawb (HR=0.63, 95% CI: 0.52-0.76; p<0.0001). The median progression free survival (PFS) of patients in the Datroway treatment group was 6.9 months, while in the chemotherapy group it was 4.9 months.
Hais txog kev nyab xeeb, 93.6% (337/360) ntawm 360 tus neeg mob hauv Datroway (6 mg / kg) pab pawg kho mob tau ntsib kev tsis zoo. Cov kev phiv tshwm sim feem ntau suav nrog xeev siab (51.1%), stomatitis (50.0%), plaub hau poob (36.4%), qaug zog (23.6%), thiab qhov muag qhuav (21.7%). Vim qhov tshwm sim ntawm tus kab mob ntsws interstitial (ILD), suav nrog cov neeg mob tuag taus, hauv cov neeg mob tau txais kev kho Datroway, nws raug nquahu kom siv Datroway hauv kev sib koom tes nrog cov kws kho mob ua pa.
Datroway yog ADC uas ua ke nrog tib neeg, Trop2 tsom rau cov tshuaj tiv thaiv kab mob monoclonal nrog cov tshiab DNA topoisomerase I inhibitors (DXd). DXd muaj cov txheej txheem tshwj xeeb ntawm kev ua, nrog rau 10 npaug ntxiv hauv kev ua haujlwm piv rau cov tshuaj siv tshuaj kho mob irinotecan. Ntxiv mus, cov tshuaj no muaj peev xwm nkag mus rau hauv cov cell membrane, tso cai rau nws tua cov qog nqaij hlav nyob ze tom qab tua cov qog nqaij hlav cancer uas nqos ADC, uas ua rau muaj 'cov nyhuv ntawm cov neeg nyob ze'.
Trop2 yog ib qho protein ntau uas tau nthuav tawm ntau yam ntawm cov qog nqaij hlav, suav nrog HR zoo, HER2 qis qhia lossis mob qog noj ntshav tsis zoo. AstraZeneca thiab Daiichi Sankyo tau ua tiav daim ntawv cog lus thaum Lub Xya Hli 2020 los koom tes hauv kev txhim kho ADC no. Tam sim no, daim ntawv thov kev lag luam ntawm Datroway rau mob qog noj ntshav tau raug tshuaj xyuas hauv Tebchaws Meskas, European Union, Tuam Tshoj thiab lwm lub tebchaws thiab cheeb tsam.
